A5029243551- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
- Immune cells in cancer
- T-cell and B-cell Immunology
- Cancer Research and Treatments
- Virus-based gene therapy research
- HER2/EGFR in Cancer Research
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Nanoplatforms for cancer theranostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Nanoparticle-Based Drug Delivery
- Cancer Genomics and Diagnostics
- RNA Interference and Gene Delivery
- Peptidase Inhibition and Analysis
- Viral Infections and Vectors
- Cancer Cells and Metastasis
- Chemokine receptors and signaling
- Mosquito-borne diseases and control
- S100 Proteins and Annexins
- Colorectal Cancer Treatments and Studies
- interferon and immune responses
Clinica Universidad de Navarra
2016-2025
Centro de Investigación Biomédica en Red de Cáncer
2017-2025
Universidad de Navarra
2016-2025
Navarre Institute of Health Research
2016-2025
University of Oxford
2023-2025
Chartered Institute of Management Accountants
2011-2023
University of Chieti-Pescara
2023
Instituto de Salud Carlos III
2018-2023
Roche (Switzerland)
2022
Bipar
2014-2021
<h3>Importance</h3> Most patients with hepatocellular carcinoma (HCC) are diagnosed advanced disease not eligible for potentially curative therapies; therefore, new treatment options needed. Combining nivolumab ipilimumab may improve clinical outcomes compared monotherapy. <h3>Objective</h3> To assess efficacy and safety of plus in HCC who were previously treated sorafenib. <h3>Design, Setting, Participants</h3> CheckMate 040 is a multicenter, open-label, multicohort, phase 1/2 study. In the...
Mechanisms of acquired resistance to immune checkpoint inhibitors (ICI) are poorly understood. We leveraged a collection 14 ICI-resistant lung cancer samples investigate whether alterations in genes encoding HLA Class I antigen processing and presentation machinery (APM) components or interferon signaling play role PD-1 PD-L1 antagonistic antibodies. Recurrent mutations copy-number changes were not detected our cohort. In one case, we found homozygous loss B2M that caused lack cell-surface...
Weak and ineffective antitumor cytotoxic T lymphocyte (CTL) responses can be rescued by immunomodulatory mAbs targeting PD-1 or CD137. Using Batf3(-/-) mice, which are defective for cross-presentation of cell-associated antigens, we show that BATF3-dependent dendritic cells (DC) essential the response to therapy with anti-CD137 anti-PD-1 mAbs. mice failed prime an endogenous CTL-mediated immune toward tumor-associated including neoantigens. As a result, could not amplify any therapeutically...
Abstract Summary: Cancer immunotherapy has great promise, but is limited by diverse mechanisms used tumors to prevent sustained antitumor immune responses. Tumors disrupt antigen presentation, T/NK–cell activation, and homing through soluble cell-surface mediators, the vasculature, immunosuppressive cells such as myeloid-derived suppressor regulatory T cells. However, many molecular preventing efficacy of immunity have been identified can be disrupted combination immunotherapy. Here, we...